

Using LLMs to label medical papers according to the *CIViC* evidence model

Markus Hisch, Xing David Wang
Humboldt-Universität zu Berlin
xing.wang@informatik.hu-berlin.de

Abstract

We introduce the sequence classification problem *CIViC Evidence* to the field of medical NLP. *CIViC Evidence* denotes the multi-label classification problem of assigning labels of clinical evidence to abstracts of scientific papers which have examined various combinations of genomic variants, cancer types, and treatment approaches.

We approach *CIViC Evidence* using different language models: We fine-tune pretrained checkpoints of BERT and RoBERTa on the *CIViC Evidence* dataset and challenge their performance with models of the same architecture which have been pretrained on domain-specific text. In this context, we find that BiomedBERT and BioLinkBERT can outperform BERT on *CIViC Evidence* (+0.8% and +0.9% absolute improvement in class-support weighted F1 score). All transformer-based models show a clear performance edge when compared to a logistic regression trained on bigram *tf-idf* scores (+1.5 – 2.7% improved F1 score).

We compare the aforementioned BERT-like models to OpenAI’s GPT-4 in a few-shot setting (on a small subset of our original test dataset), demonstrating that, without additional prompt-engineering or fine-tuning, GPT-4 performs worse on *CIViC Evidence* than our six fine-tuned models (66.1% weighted F1 score compared to 71.8% for the best fine-tuned model). However, performance gets reasonably close to the benchmark of a logistic regression model trained on bigram *tf-idf* scores (67.7% weighted F1 score).

1 Introduction

Rare malignancies continue to pose unique challenges in cancer treatment (Ashley et al., 2015). Addressing this phenomenon, tools like *next-generation sequencing* (NGS) have become essential for identifying specific genomic variants

that inform targeted therapies (Leichsenring et al., 2019).

As NGS has permeated clinical practice, *Molecular Tumor Boards* (MTBs) have emerged as collaborative forums, uniting multidisciplinary teams of oncologists, pathologists, bioinformaticians, and other researchers. These boards are dedicated to analyzing and discussing cases where standard treatment options like chemotherapy have proven ineffective. The central objective of MTBs is to develop highly personalized treatment strategies based on thorough analysis of a patient’s genomic variants (Luchini et al., 2020).

Hence, access to relevant data relating genomic variants and tumor characteristics with druggability is paramount for creating effective treatment plans. Such data is usually collected by consulting medical databases combined with extensive literature research (Starlinger et al., 2018).

The sequence classification problem *CIViC Evidence* *CIViC* is an open database curated by experts, facilitating clinical interpretations of variants in cancer. It includes a table (*Evidence Table*) mapping tuples of genetic variants, concrete cancer manifestations, and treatment approaches to labels indicating different levels of clinical evidence. The label of clinical evidence is inferred from peer-reviewed papers that have investigated underlying variants and their clinical response to treatments (Griffith et al., 2017).

However, this process of data labeling still relies on manual expertise. Given an ever-growing corpus of relevant research literature, this approach faces scalability challenges.

Addressing this issue, Machine Learning Systems, particularly Large Language Models (LLMs), have

shown promising results across a variety of clinical language understanding tasks, including sequence classification, albeit with limitations (Wang et al., 2023).

We propose and compare different Natural Language Processing (NLP) models, all based on the transformer architecture (Vaswani et al., 2017), to predict these evidence levels using the abstract of the paper associated to it in the *CIViC Evidence Table*. We will refer to this dataset and to the corresponding classification problem as *CIViC Evidence*. Trained models can then be leveraged to automatically infer labels of clinical evidence from medical publications and abstracts, thus reducing the need for manual data labeling.

Research questions In the context of the sequence classification problem *CIViC Evidence*, we seek to answer the following questions:

1. Can transformer-based language models outperform competitive models which are not based on transformers?
2. Do different transformer-based models benefit from *domain-specific pretraining*?
3. Do BERT-like models benefit from increasing context-width (see Biomed-RoBERTa-Long in section 4.2) given that a significant portions of abstracts in *CIViC Evidence* are longer than the 512 token window of BERT or RoBERTa?
4. Can *very large language models* like GPT-4 outperform fine-tuned BERT-based language models in a few-shot setting (section 2.4)?

Main contributions We show that various transformer-based models can significantly outperform *tf-idf score* based logistic regressions on *CIViC Evidence*. Furthermore, we demonstrate that domain-specific pretraining can further increase performance of BERT and RoBERTa on *CIViC Evidence*. We propose a new RoBERTa-based transformer (Biomed-RoBERTa-Long) with a context width of 1024 tokens (compared to 512 tokens for Biomed-RoBERTa). We perform domain-specific pretraining of this model on *long PubMed* abstracts and show that this increases downstream performance in the context of *CIViC Evidence*. Lastly, we demonstrate that GPT-4, in a few-shot setting without additional prompt-engineering or fine-tuning, performs significantly worse on *CIViC*

Evidence than our fine-tuned models based on BERT or RoBERTa. Our code is made accessible as a Github repository at <https://github.com/GMahlerTheTragic/civic>.

2 Background

2.1 The role of automatic evidence classification in clinical practice

In this section, our aim is to underscore the importance of automated inference of evidence labels from pertinent research. Fundamentally, cancer is a disease caused by genetic alterations, which contribute to uncontrolled proliferation of malignant cells. However, cancer is seldomly caused by a single genetic mutation, but by a series of mutations affecting multiple genes, combined with failed DNA repair and apoptosis mechanisms. Proto-oncogenes and tumor suppressor genes are the primary targets of carcinogenic processes. As they are essential for regulating cell proliferation and differentiation, alterations in their genetic structure can lead to faulty gene products and unbalanced gene expression, eventually resulting in cell degeneration (Horm, 2020).

Modern research in cancer and its causes has identified correlations between the presence of various genetic alterations and the occurrences of particular kinds of cancer. Precision oncology tries to exploit these links by applying treatments targeting these molecular causes of cancer. To facilitate this approach, NGS tools usually sequence a patient’s entire genome aiming at identifying the unique combination of genetic alterations associated with their disease (Shin et al., 2017).

As a next step, groups of specialists (*Molecular Tumor Boards*) can perform extensive literature research with the goal of identifying promising treatment approaches for the patient’s illness (Luchini et al., 2020).

Practitioners are confronted with the dual task of handling the large variety of genomic alterations linked to a particular disease, while also staying abreast of the ever-growing body of research linked to these alterations. In fact, a simple PubMed keyword search relating *Pancreatic Cancer* with different molecular profiles yields tens of thousands of potentially relevant research publications (Fig. 1). Adding the different medica-




Figure 1: PubMed keyword search matches for Pancreatic Cancer and various molecular profiles

tion options to this analysis further complicates the picture: Treating physicians are confronted with a plethora of research on hundreds of combinations of different molecular profiles and treatment approaches. Moreover, these research corpora have often been growing at an exponential rate (Fig. 2). In practice, only few of these publications are relevant for an individual patient’s treatment. Consequently, it is imperative to pinpoint research pertinent to the specific case at hand, particularly research that advocates treatment approaches supported by robust clinical evidence.

Precision oncology information systems (Starlinger et al., 2018) aim to streamline this process by automatically identifying and filtering research with significant clinical implications, thereby enhancing targeted patient care. Achieving this goal can be accomplished through a two-step approach. Initially, text-mining software can scan research articles, focusing on the intersection of malignant diseases, genomic alterations, and treatment strategies. Subsequently, a language model can assign levels of clinical evidence to these articles. Once labeled, these articles form the foundation of a curated database, accessible to healthcare providers. While the creation of such databases traditionally relies on manual curation, integrating automatic evidence classification can potentially improve both, the quality and economic feasibility, of compiling

these resources (Hamamoto et al., 2022).

2.2 Natural Language Processing using Transformers

Since the groundbreaking introduction of the transformer architecture in Vaswani et al. (2017), the field of Natural Language Processing (NLP) has experienced significant and continuous progress.

Notably, Google’s BERT (Devlin et al., 2019) model and OpenAI’s GPT model family (Radford, Narasimhan, et al., 2018; Radford, J. Wu, et al., 2019; Brown et al., 2020; OpenAI, 2023) can be seen as key milestones, culminating in the recent achievements of GPT-3.5 and GPT-4.

Transformers can be roughly classified into *encoder-only* transformers (BERT-like models, as in Devlin et al. (2019)), *decoder-only* transformers (GPT-like models, as in Radford, Narasimhan, et al. (2018)), and *encoder-decoder* transformers (the *original* transformer, as introduced in Vaswani et al. (2017)). Encoder-only transformers have traditionally excelled in language comprehension tasks such as sequence classification, while decoder-only architectures have been used (and continue to be used) for generative language tasks. Encoder-decoder transformers can be used for sequence-to-sequence tasks, such as machine




Figure 2: PubMed keyword search matches for Pancreatic Cancer and BRCA1 Mutation over time

translation (Lin et al., 2021).

Fig. 3 shows a prototypical transformer architecture for either an encoder-only or decoder-only architecture (depending on the attention pattern used). Encoder-only architectures generally make use of *unmasked* self-attention, whereas decoder-only architectures require the use of *masked* self-attention. We kindly refer the reader to relevant literature discussing particular *transformer flavours* in greater detail (e.g. (Lin et al., 2022)). Furthermore, it seems prudent to mention that transformers have found applications in other fields of machine learning beyond NLP. This includes the field of Computer Vision (Dosovitskiy et al., 2021). Some of the sections which follow (e.g. *Tokenization*) may not be applicable to these kinds of transformers.

2.3 Task-specific prediction heads: Pretraining & Fine-tuning

Large Language Models are typically pretrained on vast corpora of mixed-domain text, enabling them to develop a comprehensive understanding of language. One major advantage of this approach is the possibility to leverage unsupervised training on text data by means of e.g. *masked language modeling* as in Devlin et al. (2019), eliminating the need for large labeled datasets.

Pretraining by means of masked language modeling (MLM)

The MLM objective involves randomly masking a certain percentage of the input tokens in a sequence and tasking the model with predicting the masked tokens based on the context provided by the surrounding words. This self-supervised learning approach allows language models to learn rich, contextualized representations that capture syntactic, semantic, and contextual nuances in language. For example, the training procedure using MLM for BERT (Devlin et al., 2019) involves the following steps:

1. **Masking Tokens:** Randomly, a certain percentage (15% in Devlin et al. (2019)) of tokens in the sequence are masked, meaning they are replaced by a special token `<MASK>`.
2. All masked tokens are set to a random token from the vocabulary with a probability of 10% and reverted to the original unmasked token with a probability of 10%.
3. The token sequence is processed by an encoder-only transformer and the model is trained to predict the original token from the encodings of the masked tokens. Here, the corresponding cross-entropy loss function only takes into account the positions of masked tokens (which is different from e.g. *auto-encoders*).




Figure 3: Possible architecture of encoder-only and decoder-only transformers

This learning objective allows for the use of unmasked self-attention without information leak. Architecture-wise this training procedure is realized using a linear layer which realizes the following transformation:

$$\text{Linear}(X) = XW \quad (1)$$

Let $X \in \mathbb{R}^{n \times e}$ denote the encodings of the input sequence after all transformer blocks have been applied. The application of $W \in \mathbb{R}^{e \times v}$ allows for the computation of a logit matrix. The maxima over the rows denote the predicted token for each input token. Here, n , e , v denote context width, embedding dimension (assumed to be constant for all transformer blocks) and vocabulary size, respectively.

Domain-specific pretraining Additionally, in domains like the biomedical field with ample text data available, models have been exclusively pre-trained on domain-specific text corpora (for example using only papers from *PubMed*). Examples include BiomedBERT (Gu et al., 2021), LinkBERT (Yasunaga et al., 2022), ClinicalLongformer (Li et al., 2022), and BioMedLM (Bolton et al., 2022). These models have shown elevated performance on various biomedical benchmarks when compared to their mixed-domain counterparts.

Fine-tuning for sequence classification To apply pretrained models to specific tasks like *sequence classification*, transfer learning in the form of fine-tuning can be employed. This

involves updating model weights through gradient descent and adding custom model layers (e.g. *Classification Heads*), learning from labeled datasets curated for the concrete task at hand.

For a multi-label classification task (i.e. multiple labels can be assigned to the same item - labels are not mutually exclusive) comprised of l different labels the classification-specific model head needs to output a logit vector of dimension l .

In BERT-like models (including RoBERTa) this is achieved by first pooling the final encodings and then applying a last linear transformation. One option to perform this, is to only keep the encoding of the <BOS> token (<CLS> in Devlin et al. (2019)). The final logit computation is then performed as:

$$\text{logits} = e_{\text{cls}}W \in \mathbb{R}^l \quad (2)$$

where $e_{\text{cls}} \in \mathbb{R}^{1 \times e}$ denotes the encoding of the <CLS> token and $W \in \mathbb{R}^{e \times l}$. To perform the actual label prediction, logit entries for every class can be classified as *positive* if the value is greater than a certain class-specific threshold (e.g. zero). Otherwise, they are classified as *negative*.

2.4 Few-shot Learning

As models have grown larger, the new learning paradigm of *In-Context Learning* (Brown et al., 2020) has grown in significance, presenting an alternative to domain- and task-specific fine-tuning. In such settings, models are presented with

prompts including examples of a *context* (task description) and the correct output/label. Models are then expected to solve further instances of the task. As opposed to model fine-tuning, no gradient updates are performed and example datasets are usually much smaller.

In this setting, the term *N-shot learning* refers to the number of examples used to condition the model on the task it is expected to solve.

Special cases include *zero-shot* and *one-shot* learning. Models like GPT-3.5 and GPT-4 have shown promising results in biomedical language-processing tasks despite being trained on general-domain data (Wang et al., 2023) hinting at strong *In-Context Learning* capabilities.

2.5 Explainable AI (XAI) by means of Integrated Gradients

As machine learning systems become more integrated into various aspects of life, understanding why and how these systems reach specific conclusions is imperative for fostering trust, accountability, and ethical use.

Explainable AI (XAI) methods formally try to solve the problem of assigning attributions towards an output to inputs of machine learning methods. Integrated Gradients, as introduced in Sundararajan et al. (2017), is an attribution algorithm which addresses certain shortcomings of previous methods. That is, many attribution algorithms do not fulfill three fundamental axioms which are identified as desirable for any attribution algorithms designed for deep neural networks:

Axiom (Sensitivity(a)). *An attribution method satisfies Sensitivity(a), if, for every input and baseline that differ in one feature but have different predictions, the differing feature is given a non-zero attribution.*

Axiom (Sensitivity(b)). *If the function implemented by the deep network does not depend (mathematically) on some variable, then the attribution to that variable is always zero.*

Axiom (Implementation Invariance). *Attribution methods should be implementation invariant, i.e., the attributions are always identical for two functionally equivalent networks.*

Integrated Gradients attributes a model prediction to its features by integrating the gradients of

the model output with respect to the input features along a straight path from a baseline to the input. Formally,

$$\text{ig}_i(x) = (x_i - x'_i) \int_0^1 \frac{\partial F(x' + \alpha(x - x'))}{\partial x_i} d\alpha$$

Here, x is a vector of input features and x' is a corresponding vector of baseline features. In the context of linear models, this integration simply corresponds to the product of inputs and coefficients (if we assume the zero-vector as baseline).

Choosing a non-informative baseline provides a mechanism of translating these attributions to absolute attributions for the input vector x . For image models, a simple black image is a frequent choice. For text models, choosing an all-zero embedding vector provides an uninformative choice, since it will lead to an uniform distribution at the final softmax layer. Another choice for text models is to choose the baseline to be a sequence comprised of only padding tokens wrapped with <BOS> and <EOS> tokens.

In the context of transformer architectures, the integrals shown above can be computed with respect to each entry of the matrix resulting from embedding and positional encoding. They can then be summed over the embedding dimension e to provide attributions on the token level.

3 Related work

The biomedical language domain has been a prominent target of inference in Natural Language Processing (NLP) for the last 40 years (Friedman et al., 2013). Adding to its allure is the potential for a multitude of real-world applications. These applications encompass diagnostic assistance, automated knowledge extraction from textual sources, and decision-making support in treatment scenarios (Wang et al., 2023).

While the field of biomedical NLP has benefited from recent advances in general-domain NLP, substantial amounts of digitized in-domain text has fueled research on the topic of domain-specific adaptations of language models. Notable examples of this approach include BiomedBERT (Gu et al., 2021) and BioLinkBERT (Yasunaga et al., 2022). Gu et al. (2021) trained the original

BERT-architecture, as in [Devlin et al. \(2019\)](#), exclusively on abstracts from PubMed. The resulting model has been shown to outperform BERT on various benchmarks of clinical language understanding. BioLinkBERT follows a similar idea, additionally exploiting the rich citation (*link*) structure of *PubMed* papers.

One striking benefit of domain-specific pretraining which the authors outline in [Gu et al. \(2021\)](#) is the possibility to train domain-specific tokenizers: The tokenizer underlying BiomedBERT recognizes the word "*Imatinib*" (a drug for treating leukemia ([Nida Iqbal and Naveed Iqbal, 2014](#))) as a whole token, whereas the BERT tokenizer would produce the three tokens "*im atin ib*".

These encoder-only models have to be fine-tuned on concrete clinical language understanding tasks such as medical *multiple choice* tasks. They are also natural candidates to be fine-tuned on text classification tasks akin to *CIViC Evidence*.

With the advent of very large *closed weight* language models such as GPT-3.5 ([Brown et al., 2020](#)) and GPT-4 ([OpenAI, 2023](#)), fine-tuning has become less practical. This is due to the fact that exact model snapshots and architectures may not be available and classical fine-tuning for all sorts of downstream applications like *CIViC Evidence* may be prohibitively expensive. On the other hand, these models have shown impressive *few-shot* performance across a wide range of biomedical language understanding tasks without further fine-tuning ([Wang et al., 2023](#)).

Regarding the classification problem *CIViC Evidence*, we believe that we are the first to explore this exact problem. However, similar studies related to the prediction of clinical evidence levels from medical papers have been performed. The methods used reflect the state of the art in medical NLP at the time.

In [Regev et al. \(2002\)](#), the authors use a rule-based *information extraction* model to determine whether biomedical papers from a corpus dealing with the genetics and molecular biology of *Drosophila* (fruit flies) contain experimental evidence for certain gene products. This model was the winner of the 2002 *KDD cup*, achieving an F1 score of 67% on the Gene Product task.

[Kim et al. \(2011\)](#) use *conditional random fields* to first extract relevant sentences from biomedical paper abstracts and then classify these into labels roughly corresponding to the *PICO (Population Intervention Comparison Outcome)* schema commonly used in evidence based medicine. The authors report F1 scores between 66.9% and 80.9% for their classification problems.

In [Morid et al. \(2016\)](#), a kernel-based Bayesian Network is used to predict if sentences extracted from a collection of medical papers are clinically useful. The authors propose an intricate feature engineering approach using various biomedical NLP tools like *MedTagger*¹ and *SemRep* ([Kilicoglu et al., 2020](#)). These features serve as input to the downstream Bayesian Network which achieves a performance of 78% F1 score.

The *Evidence Inference task* as established in [Lehman et al. \(2019\)](#) and expanded to abstract-only based prediction in [DeYoung et al. \(2020\)](#) can serve as a proxy to *CIViC Evidence* and provide guidance on which performance levels (the authors report 0.776 macro-F1 score) can be achieved by various model architectures (including but not limited to transformer based models).

In [Lever et al. \(2019\)](#), the authors propose a text mining strategy to extract papers which fit the *CIViC evidence* model from a large corpus of papers from the biomedical domain. This includes categorizing papers into the four *CIViC evidence types*² (note that these denote a concept distinct from the *evidence levels*) using comparatively simple NLP models. A notable limitation of the approach presented in [Lever et al. \(2019\)](#) is that the classification relies on a single extracted sentence, which must encompass all the relevant information necessary for evidence type annotation.

4 Methodology

In this section, we present our methodology for *CIViC Evidence* in more detail. This includes providing an examination of the dataset, outlining any subsequent processing steps. Additionally, a comprehensive description of the machine learning architectures employed to address the classification

¹<https://github.com/medtagger/MedTagger>

²<https://civic.readthedocs.io/en/latest/model/evidence/type.html#understanding-evidence-types>

problem is presented.

4.1 The Dataset *CIViC Evidence*

Sample entries from this *Evidence Table* of the *CIViC* database³ are shown in Tab. 1:

Evidence IDs are always linked to one relevant publication (usually retrievable from the online library *PubMed*⁴) from which the evidence levels have been extracted by expert judgement. The official *CIViC* documentation⁵ (see *Understanding Evidence Levels*) defines five evidence levels as shown in Tab. 2.

It is worth mentioning that one abstract can be associated with multiple evidence items. This may be the case when an abstract deals with multiple therapies, molecular profile, or cancer manifestations, at once.

For model training and evaluation we use a self-compiled version of *CIViC Evidence* retrieved via the *CIViC* GraphQL-API⁶. We include evidence items with curation status *Accepted*, as well as those with status *Under Review* to not reduce the amount of available training data. From 10109 items retrieved via the API, we remove all items which meet one or more of the following criteria:

- Abstract text or evidence level are not populated.
- The combination of abstract, disease name, significance column, molecular profile name, and therapy names is non-unique.
- Either of disease name, significance column, molecular profile name, or therapy names is not populated.

As a next step, we compile the data for *multi label classification*: For every abstract, we compile boolean variables for all evidence levels, indicating whether the abstract is associated with the evidence level or not. We base evidence level predictions solely on the abstract of the paper associated to it in the *CIViC Evidence* table. As of 2024/02/04, this yields a dataset containing 3369 items.

³<https://civicdb.org/evidence/home>

⁴<https://pubmed.ncbi.nlm.nih.gov/>

⁵<https://civic.readthedocs.io/en/latest/model/evidence/level.html#understanding-evidence-levels>

⁶<https://civicdb.org/api/graphiql>

The occurrences of each of the five evidence levels in this version of *CIViC Evidence* are highly biased towards the three classes in the middle, as shown in Tab. 3. To take into account this class imbalance, we make use of a 80%-10%-10% train-validation-test split which tries to maintain overall class probabilities.

The length of the token sequence which transformer based language models can process is limited (e.g. BERT can process no more than 512 tokens in one forward pass). A total of 207 abstracts (6.1 %) in *CIViC Evidence* are longer than 512 tokens using the BiomedBERT tokenization strategy as in (Gu et al., 2021). We call these abstracts *long abstracts* in the context of *CIViC Evidence*.

It is worth mentioning, that both, disease name, and molecular profile, carry discriminative information about the evidence class. To illustrate this phenomenon, we show examples in Fig. 4. As a consequence, we decide to not use any further metadata for evidence level prediction. We test abilities of language models to infer the label purely from related abstracts.

4.2 Machine Learning Models

We outline our approach to the sequence classification problem *CIViC Evidence* in Fig. 5: *PubMed* paper abstract are fed into an encoder-only transformer based on BERT or RoBERTa. Input tokens are encoded and solely the encoding of the <CLS> token is used in a final linear prediction layer (as is common practice in the literature (Devlin et al., 2019)).

The classification head outputs *logits* for each evidence level which can be turned into class probabilities if desired by applying a sigmoid function. If the predicted probability is larger than a predefined threshold, the prediction is that an abstract is related to the evidence level in question.

The following paragraph summarizes the models we compare regarding their performance on *CIViC Evidence*.

Table 1: Sample entries from the *Evidence* table of the *CIViC* database

Id	Molecular Profile	Disease	Therapy	Evidence Level	PubMed Id
EID238	EGFR T790M	Non-small Cell Lung Carcinoma	Erlotinib	A - Validated Association	25668228
EID1246	FGFR1 N546K	Ewing Sarcoma Of Bone	Ponatinib	E - Inferential Association	26179511
EID7033	ABL1 BCR::ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	C - Case Study	17264298




Figure 4: Evidence level distribution given two distinct disease names and molecular profiles

BERT & RoBERTa pretrained on mixed-domain text data We leverage pretrained versions of the BERT⁷ and RoBERTa⁸ models. These models have been pretrained on text data pulled from the web, covering potentially a wide variety of domains.

We fine-tune these models to solve *CIViC Evidence*. BERT is an encoder-only transformer with $N = 12$ transformer blocks with $e = 768$, $h = 768$, which uses the *GELU* activation function (Devlin et al., 2019). It was pretrained using *masked-language-modeling* as described above.

⁷We use the following snapshot: <https://huggingface.co/bert-base-uncased>

⁸We use the following snapshot: <https://huggingface.co/roberta-base>

In addition, pretraining included an objective called *Next Sentence Prediction*. This objective aims to train a model to predict whether a given pair of sentences appears consecutively or not within a text corpus, hoping to enhance the model’s understanding of context and coherence in language (Devlin et al., 2019).

The authors of Liu et al. (2019) introduce RoBERTa, improving the original BERT model by extending the training duration on a larger dataset, employing smaller batch sizes. The architecture of both models, however, is nearly identical. Both models have a maximum context length of 512 tokens. Input strings which are longer than 512 tokens are truncated.

Table 2: The five different levels of clinical evidence as used in the *CIViC* project

Level	Name	Definition	Description
A	Validated association	Proven/consensus association in human medicine	Validated associations are often in routine clinical practice already or are the subject of major clinical trial efforts
B	Clinical evidence	Clinical trial or other primary patient data supports association	The evidence should be supported by observations in multiple patients. Additional support from functional data is desirable but not required
C	Case study	Individual case reports from clinical journals	The study may have involved a large number of patients, but the statement was supported by only a single patient. In some cases, observations from just a handful of patients (e.g. 2–3) or a single family may also be considered a case study/report
D	Preclinical evidence	In vivo or in vitro models support association	The study may have involved some patient data, but support for this statement was limited to in vivo or in vitro models (e.g. mouse studies, cell lines, molecular assays, etc.)
E	Inferential association	Indirect evidence	The assertion is at least one step removed from a direct association between a molecular profile (variant) and clinical relevance

Table 3: Number of class occurrences in our version of *CIViC Evidence*

	A	B	C	D	E
Overall	150 (4.5%)	1363 (40.5 %)	1135 (33.7%)	948 (28.1%)	44 (1.3 %)
Train	115 (4.3%)	1091 (40.5 %)	908 (33.7%)	759 (28.1%)	36 (1.3 %)
Validation	18 (5.3%)	136 (40.4 %)	113 (33.5%)	95 (28.2%)	4 (1.2 %)
Test	17 (5.0%)	136 (40.4 %)	114 (33.8%)	94 (27.9%)	4 (1.2 %)

BiomedBERT, BioLinkBERT & Biomed-RoBERTa pretrained on biomedical text We compare the performance of BiomedBERT⁹ (Gu et al., 2021), BioLinkBERT¹⁰ (Yasunaga et al., 2022), and Biomed-RoBERTa¹¹ (Gururangan et al., 2020) to their respected mixed-domain variant.

Architecture-wise these models are identical to the mixed-domain versions discussed above. However, they have been pretrained on texts from the biomedical domain. In the case of Biomed-

RoBERTa, pretraining is first performed on general text data and then continued on biomedical text data. This is a key difference to BiomedBERT and BioLinkBERT which have exclusively been pretrained on biomedical text.

BiomedBERT and BioLinkBERT also come with domain-specific tokenizers which allows them to represent words from the biomedical jargon as entire tokens, whereas Biomed-RoBERTa uses the vanilla RoBERTa tokenizer. We conjecture that domain-specific pretraining leads to a measurable performance gain over the mixed-domain base models.

⁹We use the following snapshot: <https://huggingface.co/microsoft/BiomedNLP-BiomedBERT-base-uncased-abstract>

¹⁰We use the following snapshot: <https://huggingface.co/michiyasunaga/BioLinkBERT-base>

¹¹We use the following snapshot: https://huggingface.co/allenai/biomed_roberta_base




Figure 5: Predicting labels of clinical evidence from abstracts of medical publications. Shown abstract from J.-Y. Wu and Shih (2016)

Biomed-RoBERTa-Long pretrained on long PubMed abstracts One limitation of BERT-based models (including RoBERTa-based models) is their limited context length of 512 tokens. We propose a new domain-specific model, *Biomed-RoBERTa-Long*, which can handle sequences with a maximum length of 1024 tokens.

Starting from a pretrained Biomed-RoBERTa snapshot we first adjust the embedding layer to handle 1024 tokens and reinitialize its weights to random values. In the same manner as in Beltagy et al. (2020), we duplicate the first 512 positional encodings and concatenate the resulting two identical blocks to extend the positional encodings to 1024 tokens. The rest of the model stays unmodified compared to the last Biomed-RoBERTa snapshot.

We then perform continued domain-specific pre-training on a corpus of *long* PubMed abstracts¹². This corpus consists of $\sim 800,000$ abstracts which are comprised of at least 750 tokens each. We conjecture that this model should lead to further increased downstream performance compared to Biomed-RoBERTa. This approach is conceptually similar to Longformer (Beltagy et al., 2020), which

uses a windowed version of self-attention in order to scale to even longer input lengths (up to 4096 tokens).

GPT-4 pretrained on general data combined with N-shot learning We evaluate how well OpenAI’s GPT-4 (OpenAI, 2023) can perform on *CIViC Evidence* in an N-shot learning setting. To this end, we leverage OpenAI’s APIs¹³ exposing GPT-4 with a context length of 128,000 tokens¹⁴. This approach allows for an evaluation of In-Context Learning capabilities of state-of-the-art LLMs as applied to *CIViC Evidence*. No domain-specific pretraining is used, neither is the model fine-tuned for *CIViC Evidence*.

To limit the scope of this thesis, we only use *standard prompting strategies* (i.e. a prompt aiming at obtaining a direct answer to our classification problem from the model) and leave the evaluation of more sophisticated prompting strategies such as *Chain-of-Thought-Prompting* or *Self-Questioning-Prompting* (Wang et al., 2023) to future work. The exact prompt we use is shown in Fig. 6.

¹²<https://huggingface.co/datasets/pubmed>

¹³<https://platform.openai.com/docs/api-reference>

¹⁴gpt-4-0125-preview as listed here: <https://platform.openai.com/docs/models/gpt-4-and-gpt-4-turbo>

4.3 Evaluation setup

We base model evaluation on both, *intra evidence level* F1 scores, and *support-weighted* global F1 scores. For each class $c \in \{A, B, C, D, E\}$, we have:

$$F_{1,c} = 2 \cdot \frac{\text{precision}_c \cdot \text{recall}_c}{\text{precision}_c + \text{recall}_c} \quad (3)$$

$$\text{precision}_c = \frac{\text{TP}_c}{\text{TP}_c + \text{FP}_c} \quad (4)$$

$$\text{recall}_c = \frac{\text{TP}_c}{\text{TP}_c + \text{FN}_c} \quad (5)$$

Here, TP, FP, FN are the numbers of *true positives*, *false positives*, and *false negatives*, respectively. We follow the convention to define $F_{1,c}$ to be zero, should both, recall and sensitivity be zero.

The *support-weighted* global F1 score is defined to be:

$$F_1 = \sum_{c \in \{A, B, C, D, E\}} w_c F_{1,c} \quad (6)$$

$$w_c = \frac{\text{support}(c)}{\sum_{k \in \{A, B, C, D, E\}} \text{support}(k)} \quad (7)$$

Here, $\text{support}(c)$ simply denotes the number of samples which are tagged with evidence class c .

Classification thresholds (potentially different from 0.5) per evidence level are calibrated on the *validation* dataset to optimize intra-class F1 scores. Reported metrics are then calculated, post inference, on the test dataset. We report averages over five random seeds to account for the stochastic influence of the neural network training procedure (e.g. weight initialization).

5 Results & Comparative study

5.1 Continued pretraining of Biomed-RoBERTa-Long

We initialize Biomed-RoBERTa-Long from the last Biomed-RoBERTa snapshot as described in the previous section. Following the authors of [Beltagy et al. \(2020\)](#), we continue pretraining on long abstracts from *PubMed* for 3,000 gradient update steps where each step accounts for processing 2^{18} tokens. We report the *masked-language-modeling*¹⁵ loss on 3,000 randomly held-out abstracts from our pretraining corpus before and after pretraining in Tab. 4: The benchmark MLM-

¹⁵Essentially a variant of cross-entropy which only takes into account masked out tokens ([Devlin et al., 2019](#)).

Table 4: *MLM-loss* of Biomed-RoBERTa-Long & Biomed-RoBERTa before and after pretraining on long *PubMed* abstracts

Model	\mathcal{L}_{MLM}
BioMed-RoBERTa	1.032
BioMed-RoBERTa-Long	1.908
+3K gradient updates	0.994

loss of 1.032 for Biomed-RoBERTa matches well with the loss that the authors of Biomed-RoBERTa report in Tab. 1 of [Gururangan et al. \(2020\)](#) for a test dataset from the biomedical domain and their implementation of Biomed-RoBERTa (they report an MLM-loss of 0.99).

We observe that after 3,000 gradient updates, Biomed-RoBERTa-Long slightly outperforms Biomed-RoBERTa on our validation in terms of MLM-loss. Our exact pretraining setup is shown in Tab. 8 of the appendix for reproducibility purposes. We mostly use the settings suggested by the authors of [Beltagy et al. \(2020\)](#)¹⁶.

5.2 Fine-tuning results for *CIViC Evidence*

In this section, we evaluate the impact of domain-specific pretraining on downstream performance in the context of *CIViC Evidence*. In addition, we will elicit whether, *ceteris paribus*, there is a positive impact from increasing model context width. For this end, we fine-tune all BERT- and RoBERTa-based pretrained models on *CIViC Evidence*.

For all models we perform a hyperparameter search across three learning rates and two batch sizes: For each combination of learning-rate and batch size, we fine-tune the model starting from three different weight initializations for 20 epochs and early-stop at the best performing model on the validation set. We then select the hyperparameter combination with lowest average validation loss across three training runs.

As a next step we train five instances of the models using their optimal hyperparameters. Finally, for every model class, we evaluate the five resulting model runs on the test set.

¹⁶https://colab.research.google.com/github/allenai/longformer/blob/master/scripts/convert_model_to_long.ipynb

System

You are an expert on rare tumor treatments. In the following you will be presented with abstracts from medical research papers. These abstracts deal with treatment approaches for rare cancers as characterized by their specific genomic variants. Your job is to infer matching levels of clinical evidence of the investigations described in the abstract. Labels range from "A" (indicating the strongest clinical evidence) to "E" (indicating the weakest clinical evidence). A single abstract can be associated with multiple evidence levels. The definitions of the evidence levels are as follows: A: Proven/consensus association in human medicine. B: Clinical trial or other primary patient data supports association. C: Individual case reports from clinical journals. D: In vivo or in vitro models support association. E: Indirect evidence. You will answer machine-like with a list of 0 vs. 1 flags for every of the five evidence levels indicating if the abstract matches an evidence level or not. In the following you will be presented with examples. Note the first entry of the result list should correspond to evidence level "A" and the last entry of the result list should correspond to evidence level "E".

User

Extract the level of clinical evidence from this abstract:
Abstract containing at least evidence level A

Assistant

[1, 0, 0, 0, 0]

...

User

Extract the level of clinical evidence from this abstract:
Abstract containing at least evidence level E

Assistant

[0, 0, 1, 0, 1]

User

Extract the level of clinical evidence from this abstract:
Abstract for evidence item to be classified

N examples
per evidence level

Figure 6: Prompt for GPT-4 used for few-shot prediction of *CIViC* evidence levels

It is worth mentioning that, for every model, we calibrate an optimal probability threshold per evidence level based on the underlying *precision-recall* curve. That is, for every evidence level, we choose the threshold which maximizes the F1 score on the *validation* dataset.

We report here the average performance across five fitted models per model class on the test dataset. The validation dataset evaluation results for the hyperparameter grid search described above are reported in Tab. 9 of the appendix. There, we also document the technical training setup for reproducibility purposes in Tab. 8.

As shown in Tab. 5, our transformer-based models clearly outperform a simple logistic regression model based on *bigram tf-idf score* features (see e.g. [Riego and Villarba \(2023\)](#) for a brief introduction). Tab. 5 shows improvements in most metrics for the models that were pretrained on biomedical text (or underwent *continued* domain-specific pretraining in the case of Biomed-RoBERTa). Our

own Biomed-RoBERTa-Long exhibits further improved downstream performance compared to Biomed-RoBERTa.

While all models perform reasonably on *CIViC Evidence* in general, performance on the rare classes *A* and *B* is significantly worse. This is expected given the lack of available training data for these two classes. Furthermore, it is important to mention that model robustness with respect to stochastic influence varies among architectures, as can be seen in Fig. 10 in the appendix. In fact, when looking at median performance, BiomedBERT is the best performing model. In this case, average performance is greatly reduced by one outlier.

5.3 Comparison with GPT-4

Given our constraint resources, evaluation of GPT-4 on our entire test dataset is unfeasible. Hence, we use a slightly different evaluation setup:

From the *CIViC Evidence* test dataset we carve out *four* items per evidence level as an additional test dataset and have OpenAI's GPT-4

Table 5: Fine-tuning results for *CIViC Evidence* by model architecture

	$F_{1,A}$	$F_{1,B}$	$F_{1,C}$	$F_{1,D}$	$F_{1,E}$	F_1
BERT	51.6	83.9	80.0	88.0	-	81.3
+BiomedBERT	58.3	84.2	81.9	87.2	-	82.1
+BioLinkBERT	61.8	84.1	81.2	87.9	-	82.2
RoBERTa	48.4	82.9	80.1	88.4	2.0	80.9
+BioMed-RoBERTa	55.3	84.3	81.8	87.8	2.4	82.2
+BioMed-RoBERTa-Long	58.2	84.7	81.6	88.3	5.9	82.5
Logistic regression (<i>tf-idf</i> features)	50.0	83.4	77.3	86.5	-	79.8

predict the matching levels in a few-shot setting. For the prompt (Fig. 6) discussed in the previous section we obtain results as presented in Tab. 6.

We report averages across three API-calls per few-shot setting. Here, for every API-call we sample N example abstracts from the *CIViC Evidence* training dataset.

The evaluation dataset remains constant and consists of the aforementioned four items per evidence level. It is important to mention that for this analysis we also evaluate the fine-tuned models on this *reduced test dataset*, hence the results do not coincide with Tab. 5.

It becomes clear that *CIViC Evidence* presents a significant challenge for GPT-4, at least without further *prompt engineering*. While performance gets close to the logistic regression based on *tf-idf scores*, it remains clearly poorer than the performance of the fine-tuned models.

We observe that F1 score performance drops when including one example per class as compared to zero-shot performance. It then increases super-linearly, peaking at $N_{shots} = 4$. Then performance starts to degrade again. Interestingly, GPT-4 can significantly outperform our models on evidence level *E*. Given the lack of proper explainability approaches for this *closed weights* model, this phenomenon is not further investigated.

6 Error analysis & Interpretability

In this section, we aim to perform a more systematic error analysis. If it underscores salient points, we supplement our exposition by findings from an explainability analysis based on *integrated*

gradients.

We begin by quantifying the *difficulty* of test dataset evidence items. To this end, Fig. 7 ranks evidence items by the number of models¹⁷ which label them correctly. Given the fact that an evidence item can be tagged with multiple evidence classes, we define *correctly* classified items to be those items, which have *all* evidence classes predicted correctly. We see that around half of the test dataset samples are labeled correctly by all models. Similarly, we also observe that a significant fraction of samples is misclassified for all models we consider.




Figure 7: Number of correctly annotating models by test dataset evidence items

Reasons for misclassification: Insufficient information in the abstract Investigating these *hard* abstracts, we find that some of them simply

¹⁷we take the median run for each model class

Table 6: Few-shot learning results of GPT-4 on *CIViC Evidence*

	$F_{1,A}$	$F_{1,B}$	$F_{1,C}$	$F_{1,D}$	$F_{1,E}$	F_1
BERT	83.7	77.3	83.6	95.0	-	70.7
+BiomedBERT	90.5	87.2	68.3	86.5	-	71.3
+BioLinkBERT	94.9	84.9	64.0	77.1	-	68.7
RoBERTa	81.6	80.2	71.7	91.1	13.3	70.9
+BioMed-RoBERTa	87.1	81.8	79.8	83.6	5.7	70.9
+BioMed-RoBERTa-Long	90.5	83.4	68.3	81.8	18.3	71.8
Logistic regression (<i>tf-idf</i> features)	50.0	83.4	77.3	86.5	-	67.7
GPT-4 (zero shot)	61.8	66.6	53.3	88.4	24.4	61.5
+1 example per class	55.6	55.6	56.0	88.6	-	53.4
+2 examples per class	61.9	64.8	51.5	74.2	16.7	56.7
+3 examples per class	86.1	38.3	63.4	72.1	50.0	57.8
+4 examples per class	90.5	59.8	69.4	59.3	61.1	66.1
+5 examples per class	79.4	39.4	52.5	62.7	45.5	53.0
+10 examples per class	76.2	48.2	22.2	36.1	45.5	45.8

do not contain enough information to classify them correctly. In these cases, the human annotator most likely read the full-text associated with the abstract and then performed the classification.

To clarify this phenomenon, it is illustrative to look at an example:

Larotrectinib can be effective in patients with ETV6-NTRK3-positive B-cell lymphoblastic leukemia, inducing prolonged molecular remission. Single-agent tyrosine kinase inhibitor treatment could be a valuable treatment option in subgroups of kinase fusion-positive ALL patients.
— (Schewe et al., 2019)

This abstract is annotated with the two evidence levels *C* and *D*. When looking at the *description* (another column in the *CIViC evidence* table) for this evidence item, we find:

Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk) revealed an unbalance translocation of the ETV6 locus. RNA sequencing of detected a cytogenetically cryptic ETV6-NTRK3 fusion. Larotrectinib therapy achieved remission of the patient’s two separate relapses. Patient

derived xenografts injected into mice and treated with Larotrectinib demonstrated significant reductions in spleen volume, blasts in spleen, and blast in bone marrow ($p < .0001$) compared to controls 25 days after injection. Larotrectinib treatment was effective regardless of the day of initiation post xenograft injection (1 day or 8 days after).’

— (Griffith et al., 2017)

Here, the *mice experiment* is the decisive factor for tagging this item with evidence label *D*. However, this information is nowhere to be found in the abstract.

In contrast to this example, we can examine the abstract of another evidence item, which is correctly labeled with evidence class *D* by *all* model classes:

We investigated the efficacy of the Wee1 inhibitor MK-1775 in combination with radiation for the treatment of pediatric high-grade gliomas (HGGs)

[...]

Finally, combined MK-1775 and radiation conferred greater survival benefit to mice bearing engrafted, orthotopic HGG and DIPG tumors, compared with treatment with radiation alone (BRAF(V600E) model $P = .0061$ and DIPG brainstem model $P = .0163$). Our

results highlight MK-1775 as a promising new therapeutic agent for use in combination with radiation for the treatment of pediatric HGGs, including DIPG.

— (Mueller et al., 2014)

In this example, the findings from *mice experiments* are explicitly mentioned.

Reasons for misclassification: Presence of adversarial tokens Tab. 10 and Tab. 11 (see Appendix) show the tokens associated with the highest attribution impact per model and evidence class for a subset of four evidence items per evidence level sampled from the test dataset.

While we do observe strong idiosyncratic influence resulting from the 20 selected examples (particularly for class *C*, tokens with high attribution mostly stem from the phrase "*Von Hippel-Lindau disease (VHL)*"), we also see that classes *A* and *B* are closely linked to vocabulary describing clinical trials on patients (which their respective evidence level definitions suggest).

Fig. 8 shows an abstract which is correctly tagged with evidence level *A*. We observe that the model puts high emphasis on the tokens *phase 3 trial*, in line with expectations. In contrast, top tokens for class *D* include the word *mice* (as in mouse experiment), and *cell* as in cell models. These words are in good agreement with the defining characteristics of evidence level *D*.

However, we observe that e.g. the word *mice* also plays some role for the (mostly incorrectly) classified samples of evidence level *E* (e.g. looking at BERT). We conjecture that models may mistake samples of evidence level *E* for samples belonging to evidence level *D* (which has mouse experiments as one possible defining characteristic). Hence, one possible conclusion is that the presence of the word *mice* might actually be seen as a kind of *adversarial* example for evidence items which do not, in fact, belong to class *D*. Phenomena like this, paired with lack of training data may partially explain poor model performance for evidence label *E*.

Degrees of similarity among model misclassifications Apart from examples which are unanimously classified correctly or incorrectly, models tend to make *different* errors, whereby a significant overlap exists. We attempt to quantify

this overlap in Fig. 9.

We see that particularly the models pretrained on mixed-domain text exhibit high degrees of overlap regarding misclassified examples. Biomed-RoBERTa and Biomed-RoBERTa-Long also share a relatively large amount of errors, which is expected, given that the models have many similarities.

On the other hand, degrees of overlap reduce when moving from the base model to the domain-specific pretrained models.

Domain-specific pretraining and tokenizers

– **An example** It seems reasonable to assume that descriptions of *randomized* clinical trials are strongly linked to class *A* and may even be a differentiator of evidence level *A* and *B*, because they present a particularly rigorous way of clinical evidence testing (Hariton and Locascio, 2018).

Interestingly, the BiomedBERT tokenizer is able to recognize the word *randomized* as a single token, presumably because it occurs in sufficiently many abstracts from its pretraining corpus *PubMed*.

The *standard* BERT-tokenizer on the other hand does not model the word *randomized* as one token.

Fig. 12 (see Appendix) shows BiomedBERT to put high emphasis on *randomized* when compared to attributions made by BERT (Fig. 11, see Appendix). While BERT wrongly classifies this example, BiomedBERT labels this item correctly as belonging to evidence level *A*. Examples like this, underline the potential benefits of domain-specific pretraining and domain-specific tokenizers for downstream classification tasks.

7 Discussion

We close our exposition by discussing alternatives to our approach as well as weaknesses and limitations. Where relevant, we include pointers to possible future work.

The choice of classification problem: Multi-class vs. Multi-label We choose to formulate *CIViC Evidence* as a multi-label classification problem. That is, evidence items can be tagged with potentially all of the five evidence classes.

[CLS] the combination of iv oside ni b - an inhibitor of mutant isoc itrate dehydrogenase 1 (id h1) - and aza ci tidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed id h1 - mutated acute myeloid leukemia . in this phase 3 trial , we randomly assigned patients with newly diagnosed id h1 - mutated acute myeloid leukemia who were in eli gi ble for intensive induction chemotherapy to receive oral iv oside ni b (500 mg once daily) and subcutaneous or intravenous aza ci tidine (75 mg per square meter of body - surface area for 7 days in 28 - day cycles) or to receive matched placebo and aza ci tidine . the primary end point was event - free survival , defined as the time from randomization until treatment failure (i . e . , the patient did not have complete remission by week 24) , relapse from remission , or death from any cause , which ever occurred first . the intention - to - treat population included 146 patients : 72 in the iv oside ni b - and - aza ci tidine group and 74 in the placebo - and - aza ci tidine group . at a median follow - up of 12 . 4 months , event - free survival was significantly longer in the iv oside ni b - and - aza ci tidine group than in the placebo - and - aza ci tidine group (hazard ratio for treatment failure , relapse from remission , or death , 0 . 33 ; 95 % confidence interval [ci] , 0 . 16 to 0 . 69 ; $p = 0 . 002$) . the estimated probability that a patient would remain event - free at 12 months was 37 % in the iv oside ni b - and - aza ci tidine group and 12 % in the placebo - and - aza ci tidine group . the median overall survival was 24 . 0 months with iv oside ni b and aza ci tidine and 7 . 9 months with placebo and aza ci tidine (hazard ratio for death , 0 . 44 ; 95 % ci , 0 . 27 to 0 . 73 ; $p = 0 . 001$) . [...]

Figure 8: BioLinkBERT token-level attributions for class A on (Montesinos et al., 2022) - correct label: A - predicted label: A




Figure 9: **Left:** Percentage of shared erroneously classified test evidence by model class. **Right:** Test set evidence items by model class - light blue: Wrongly classified, dark blue: Correctly classified

An alternative would be to include relevant *metadata* into the abstract to achieve a unique mapping of abstract, molecular profile, and treatment approaches to evidence level. However, as illustrated in section 4, this kind of metadata contains a lot of information which models can use to infer the evidence level:

In fact, if we train a simple logistic regression model on *only* this metadata (excluding the abstract itself) we will achieve weighted F1 scores of around 85%.

Including this kind of metadata becomes even more problematic when we think of real world model applications. In a realistic setting, we would use our machine learning models to label evidence data found *in the wild*. This data is not likely to be accessible in structured formats, which already exhibit annotations for molecular profile and treatment approaches. More likely, applications will try to label abstracts, which will in fact belong to multiple evidence levels at the same time, directly. This is why we deem the multi-label approach more suitable.

Adding contextual information from article full-text While inclusion of structured metadata would likely distort models from their intended applications, we do think that inclusion of parts of the underlying full-texts is thinkable and likely to improve model performance.

As discussed in the previous section, some abstracts simply do not contain the information necessary to classify them correctly. This is why we think that full-texts will eventually be necessary to push model performance beyond certain boundaries.

However, this is not without its challenges, ranging from more involved data retrieval processes to demand for drastically larger context sizes of language models. This is where classical fine-tuning may reach limits (at least for users and institutions with sharply constrained computing power) and few-shot learning of models with extremely large context widths like GPT-4-128K or Google’s *Gemini 1.5*¹⁸ (context width of up to 1,000,000 tokens) may be the the only feasible approach.

Sophisticated prompting approaches & fine-tuning of larger language models As shown in the result section, the few-shot performance of GPT-4 on *CIViC Evidence* falls short of the performance of fine-tuned models. To mitigate this, future work may consider *Self-Questioning-Prompting* as in Wang et al. (2023).

A first step towards more elaborate prompts might be to ask the model to explicitly provide reasoning

¹⁸<https://blog.google/technology/ai/google-gemini-next-generation-model-february-2024/>

for its classification decision rooted in the *CIViC* evidence level guidelines outlined in Tab. 2.

In addition, future work may also leverage OpenAI’s fine-tuning API¹⁹ to provide a fairer comparison with BERT- and RoBERTa-based models.

A further natural candidate model fine-tuning could be Stanford’s **BiomedLM** (Bolton et al., 2022) which is based on GPT-2. We omit this model in this exploration due to our constrained computational resources.

The performance of Biomed-RoBERTa-Long on long abstracts We have seen that Biomed-RoBERTa-Long is the best performing model on our test dataset (Tab. 5). The motivation behind introducing this model as a variant of Biomed-RoBERTa with doubled context length, is the fact that a significant portion of the abstracts in *CIViC Evidence* exceeds the maximum context length of Biomed-RoBERTa (512 tokens).

We would expect Biomed-RoBERTa-Long to also outperform Biomed-RoBERTa on the subset of test items which are longer than 512 tokens. Evaluation results for this subset of the test dataset are shown in Tab. 7. Contrary to our expectation, we do not observe a performance increase for Biomed-RoBERTa-Long over Biomed-RoBERTa on *long CIViC Evidence* abstracts²⁰. At this point this observation is not understood and provides an opportunity for further analysis. Moreover, it would be interesting to determine whether prolonged pretraining on long abstracts (e.g. training for 65,000 gradient updates as in (Beltagy et al., 2020)) will mitigate this phenomenon.

In addition, it is important to note that this observation does not contradict our conjecture that increased context-width should lead to improved downstream performance: Given that the test dataset of long abstracts is relatively small (20 items), results shown in Tab. 7 may lack statistical robustness. In turn, this means that most *long* abstracts remain in the train dataset. This effectively implies an increase in available training data for

Biomed-RoBERTa-Long, because it is possible that *long* training abstracts contain information after the cutoff of 512 tokens which *only* Biomed-RoBERTa-Long can leverage to learn better classification decisions. This may explain the performance increase we observe for Biomed-RoBERTa-Long on the entire test dataset. A more systematic investigation of this thematic complex, may be of value.

8 Conclusion

In this thesis we investigate the impact of (continued) domain-specific pretraining on downstream performance for a sequence classification task from the realm of biomedical NLP, *CIViC Evidence*. Our investigation is based on two popular encoder-only transformer models: BERT and RoBERTa.

We show that for *CIViC Evidence* the benefit from domain-specific pretraining can amount to up to 1% improvement on weighted F1 score. In addition, we show that without further prompt engineering, even very large LLMs such as GPT-4 cannot reach equal levels of performance on *CIViC Evidence* in a few-shot setting.

In order to process sequences longer than 512 tokens, we introduce Biomed-RoBERTa-Long as a variant of Biomed-RoBERTa which can handle 1024 input tokens. We show that this adjusted variant performs slightly better in terms of F1 score on our test dataset.

One potential opportunity for future work is to continue pretraining for more gradient updates (e.g. 65,000 as in Beltagy et al. (2020)) and see if pretraining and downstream performance can be improved further.

Our analysis shows that model performance is significantly worse on evidence levels A and E, probably owing to lack of training data and certain keywords which are indicative of other classes but tend to occur in classes A and E, as well. Future work could explore the use of up-sampling and data augmentation techniques to improve model performance for these classes.

Given our constraint computational resources we have not explored the option of fine-tuning even larger domain-specific models.

¹⁹<https://platform.openai.com/docs/guides/fine-tuning>

²⁰Abstracts longer than 512 tokens according to the Biomed-BERT tokenizer

Table 7: Fine-tuning results on *CIViC Evidence* for Biomed-RoBERTa and Biomed-RoBERTa-Long - long test abstracts only

	$F_{1,A}$	$F_{1,B}$	$F_{1,C}$	$F_{1,D}$	$F_{1,E}$	F_1
BioMed-RoBERTa	57.2	82.4	31.9	66.7	-	67.6
+BioMed-RoBERTa-Long	57.6	82.3	30.1	66.7	-	67.3

Lastly, more sophisticated prompting techniques such as *Chain-of-Thought-Prompting*, *Self-Questioning-Prompting* (Wang et al., 2023) or even fine-tuning, may be of interest for further exploring the capabilities of GPT-4 on *CIViC Evidence*.

The downstream applications of these models include auto-labeling additional medical papers on molecular tumor research, contributing to the construction of extensive knowledge bases that medical practitioners can leverage for informed decision-making. Further research can explore the option of incorporating *CIViC Evidence* classifiers as one component of elaborate *information systems*, which aim at benefitting target patient care in clinical practice.

Acknowledgements

We would like to thank Ulf Leser and Alan Akbik for their useful feedback and input.

References

- Ashley, David et al. (2015). “Accepting risk in the acceleration of drug development for rare cancers”. In: *Lancet Oncol.* 16.4.
- Beltagy, Iz et al. (2020). *Longformer: The Long-Document Transformer*. arXiv: 2004.05150 [cs.CL].
- Bolton, Elliot et al. (2022). *Stanford CRFM Introduces PubMedGPT 2.7B*. Available at <https://hai.stanford.edu/news/stanford-crfm-introduces-pubmedgpt-27b>. Last checked: 2023-06-23.
- Brown, Tom B. et al. (2020). *Language Models are Few-Shot Learners*. arXiv: 2005.14165 [cs.CL].
- Devlin, Jacob et al. (2019). *BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding*. arXiv: 1810.04805 [cs.CL].
- DeYoung, Jay et al. (2020). *Evidence Inference 2.0: More Data, Better Models*. arXiv: 2005.04177 [cs.CL].
- Dosovitskiy, Alexey et al. (2021). *An Image is Worth 16x16 Words: Transformers for Image Recognition at Scale*. arXiv: 2010.11929 [cs.CV].
- Friedman, Carol et al. (2013). “Natural language processing: State of the art and prospects for significant progress, a workshop sponsored by the National Library of Medicine”. In: *Journal of Biomedical Informatics* 46.5.
- Griffith, Malachi et al. (2017). “CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer”. In: *Nature Genetics* 49.2.
- Gu, Yu et al. (2021). “Domain-Specific Language Model Pretraining for Biomedical Natural Language Processing”. In: *ACM Transactions on Computing for Healthcare* 3.1.
- Gururangan, Suchin et al. (2020). *Don’t Stop Pre-training: Adapt Language Models to Domains and Tasks*. arXiv: 2004.10964 [cs.CL].
- Hamamoto, Ryuji et al. (2022). “Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information.” In: *Exp Hematol Oncol* 11.1.
- Hariton, Eduardo and Joseph J Locascio (2018). “Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials.” In: *BJOG* 125.13.
- Horm, Florian (2020). *Biochemie des Menschen. Das Lehrbuch für das Medizinstudium*. 8th ed. Thieme.
- Iqbal, Nida and Naveed Iqbal (2014). “Imatinib: a breakthrough of targeted therapy in cancer.” In: *Chemother Res Pract* 2014.
- Kilicoglu, Halil et al. (2020). “Broad-coverage biomedical relation extraction with SemRep”. In: *BMC Bioinformatics* 21.1.

- Kim, Su Nam et al. (2011). In: *BMC Bioinformatics* 12 Suppl 2.
- Lehman, Eric et al. (2019). “Inferring Which Medical Treatments Work from Reports of Clinical Trials”. In: *Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers)*. Minneapolis, Minnesota: Association for Computational Linguistics.
- Leichsenring, Jonas et al. (2019). “Variant classification in precision oncology”. In: *International Journal of Cancer* 145.11.
- Lever, Jake et al. (2019). “Text-mining clinically relevant cancer biomarkers for curation into the CIViC database”. In: *Genome Medicine* 11.1, p. 78.
- Li, Yikuan et al. (2022). *Clinical-Longformer and Clinical-BigBird: Transformers for long clinical sequences*. arXiv: 2201.11838 [cs.CL].
- Lin, Tianyang et al. (2021). *A Survey of Transformers*. arXiv: 2106.04554 [cs.LG].
- (2022). “A survey of transformers”. In: *AI Open* 3.
- Liu, Yinhan et al. (2019). *RoBERTa: A Robustly Optimized BERT Pretraining Approach*. arXiv: 1907.11692 [cs.CL].
- Luchini, Claudio et al. (2020). “Molecular Tumor Boards in Clinical Practice”. In: *Trends in Cancer* 6.9. ISSN: 2405-8033.
- Montesinos, Pau et al. (2022). “Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.” In: *N Engl J Med* 386.16.
- Morid, Mohammad Amin et al. (2016). “Classification of clinically useful sentences in clinical evidence resources”. In: *Journal of Biomedical Informatics* 60.
- Mueller, Sabine et al. (2014). “Targeting Wee1 for the treatment of pediatric high-grade gliomas.” In: *Neuro Oncol* 16.3.
- OpenAI (2023). *GPT-4 Technical Report*. arXiv: 2303.08774 [cs.CL].
- Peters, Solange et al. (2017). “Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.” In: *N Engl J Med* 377.9.
- Radford, Alec, Karthik Narasimhan, et al. (2018). “Improving language understanding by generative pre-training”. In: *OpenAI Blog*.
- Radford, Alec, Jeff Wu, et al. (2019). “Language Models are Unsupervised Multitask Learners”. In: *OpenAI Blog*.
- Regev, Yizhar et al. (2002). “Rule-based extraction of experimental evidence in the biomedical domain: the KDD Cup 2002 (task 1)”. In: *Sigkdd Explorations* 4.
- Riego, Neil Christian R. and Danny Bell Villarba (2023). *Utilization of Multinomial Naive Bayes Algorithm and Term Frequency Inverse Document Frequency (TF-IDF Vectorizer) in Checking the Credibility of News Tweet in the Philippines*. arXiv: 2306.00018 [cs.CL].
- Schewe, Denis M et al. (2019). “Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.” In: *Blood Adv* 3.22.
- Shin, Seung Ho et al. (2017). “Addressing the challenges of applying precision oncology.” In: *NPJ Precis Oncol* 1.1.
- Starlinger, Johannes et al. (2018). “Variant information systems for precision oncology”. In: *BMC Medical Informatics and Decision Making* 18.1.
- Sundararajan, Mukund et al. (2017). “Axiomatic Attribution for Deep Networks”. In: *arXiv e-prints*, arXiv:1703.01365. arXiv: 1703.01365 [cs.LG].
- Vaswani, Ashish et al. (2017). *Attention Is All You Need*. arXiv: 1706.03762 [cs.CL].
- Wang, Yuqing et al. (2023). *Are Large Language Models Ready for Healthcare? A Comparative Study on Clinical Language Understanding*. arXiv: 2304.05368 [cs.CL].
- Wu, Jenn-Yu and Jin-Yuan Shih (2016). “Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.” In: *Oncotargets Ther* 9.
- Yasunaga, Michihiro et al. (2022). *LinkBERT: Pre-training Language Models with Document Links*. arXiv: 2203.15827 [cs.CL].

Appendix

Table 8: Pretraining and fine-tuning training setup and hyperparameters

Hyperparameter	Continued pretraining	Civic Evidence fine-tuning
Number of steps	3000	20 epochs
Batch size per GPU	8	8/16
Gradient accumulation steps	16	0
Number of GPUs	2	2
GPU type	2x Nvidia A100 80GB	2x Nvidia A100 80GB
Effective batch size	256	16/32
Learning rate	3e-4	Unweighted Loss 1e-6/3e-6/6e-6
Learning rate optimizer	Adam	Adam
Adam epsilon	1e-6	1e-6
Adam beta weights	0.9, 0.999	0.9, 0.999
Learning rate scheduler	Linear Warmup with linear decay to zero	constant
Warmup steps	500	0
Weight decay	None	None
Max. gradient norm for gradient clipping	5.0	None

Table 9: Hyperparameter search results - best performing combinations are highlighted in bold.

Batchsize Learning Rate	16		32			
	$1e^{-6}$	$3e^{-6}$	$6e^{-6}$	$1e^{-6}$	$3e^{-6}$	$6e^{-6}$
BERT	0.243	0.224	0.221	0.273	0.228	0.231
BiomedBERT	0.208	0.204	0.206	0.223	0.205	0.210
BioLinkBERT	0.222	0.216	0.214	0.236	0.217	0.218
RoBERTa	0.228	0.226	0.228	0.238	0.227	0.223
BioMed-RoBERTa	0.216	0.213	0.211	0.225	0.213	0.215
BioMed-RoBERTa-Long	0.215	0.213	0.213	0.227	0.216	0.214




Figure 10: F1 score distribution across five fitted instances per model class

Table 10: Top ten tokens with highest explainability attribution by evidence class for the BERT-based models

	BERT		BiomedBERT		BioLinkBERT	
A	1. patients	6. median	1. primary	6. b	1. patients	6. assigned
	2. progression	7. daily	2. patients	7. 45	2. trial	7. dose
	3. dose	8. clinical	3. tidline	8. randomly	3. with	8. treatment
	4. confidence	9. months	4. aza	9. assessed	4. or	9. response
	5. survival	10. dine	5. ci	10. consistent	5. phase	10. random
B	1. the	6. hort	1. patients	6.)	1. patients	6. median
	2. survival	7. dose	2. survival	7. associated	2. %	7. (
	3. was	8. is	3. the	8. braf	3. survival	8. dlbcl
	4. progression	9. median	4. (9. trial	4. p	9. 0
	5. confidence	10. associated	5. %	10. months	5. tumor	10. progression
C	1. patients	6. patient	1. vhl	6. for	1. vhl	6. disease
	2. hl	7. a	2. two	7. association	2. patients	7. cases
	3. disease	8. ma	3. ecs	8. fusions	3. patient	8. 2
	4. with	9. who	4. report	9. boy	4. mutations	9. gene
	5. mutation	10. fusion	5. cancers	10. reported	5. mutation	10. alk
D	1. cells	6. that	1. mice	6. mutant	1. .	6. cells
	2. cell	7. therapeutic	2. r3	7. cell	2. of	7. in
	3. mice	8. of	3. models	8. lines	3. we	8. is
	4. we	9. lines	4. fgf	9. raf	4.)	9. the
	5. confidence	10. mutations	5. signaling	10. kras	5. that	10. to
E	1. mice	6. dine	1. models	6. cri	1. three	6. vhl
	2. confidence	7. daily	2. consistent	7. lines	2. associated	7. p
	3. d	8. systemic	3. kit	8. ltd	3. never	8. 1
	4. progression	9. kit	4. underpinning	9. evaluated	4. smoker	9. median
	5. lines	10. mg	5. acute	10. dab	5. ecs	10. iv

alec tin ib , a highly selective inhibitor of ana pl astic l ym ph oma kinase (al k) , has shown systemic and central nervous system (cn s) efficacy in the treatment of al k - positive non - small - cell lung cancer (ns cl c) . we investigated alec tin ib as compared with cr iz ot ini b in patients with previously un tre ated , advanced al k - positive ns cl c , including those with as ym pt oma tic cn s disease . in a randomized , open - label , phase 3 trial , we randomly assigned 303 patients with previously un tre ated , advanced al k - positive ns cl c to receive either alec tin ib (600 mg twice daily) or cr iz ot ini b (250 mg twice daily) . the primary end point was investigator - assessed progression - free survival . secondary end points were independent review committee - assessed progression - free survival , time to cn s progression , objective response rate , and overall survival . during a median follow - up of 17 . 6 months (cr iz ot ini b) and 18 . 6 months (alec tin ib) , an event of disease progression or death occurred in 62 of 152 patients (41 %) in the alec tin ib group and 102 of 151 patients (68 %) in the cr iz ot ini b group . the rate of investigator - assessed progression - free survival was significantly higher with alec tin ib than with cr iz ot ini b (12 - month event - free survival rate , 68 . 4 % [95 % confidence interval (ci) , 61 . 0 to 75 . 9] with alec tin ib vs . 48 . 7 % [95 % ci , 40 . 4 to 56 . 9] with cr iz ot ini b ; hazard ratio for disease progression or death , 0 . 47 [95 % ci , 0 . 34 to 0 . 65] ; $p < 0 . 001$) ; the median progression - free survival with alec tin ib was not reached . the results for independent review committee - assessed progression - free survival were consistent with those for the primary end point . a total of [...]

Figure 11: BERT token-level attributions for class A on (Peters et al., 2017) - correct label: A, B - predicted label: B

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; $P < 0.001$); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of [...]

Figure 12: BiomedBERT token-level attributions for class A on (Peters et al., 2017) - correct label: AB - predicted label: AB

Table 11: Top ten tokens with highest explainability attribution by evidence class for the RoBERTa-based models

	RoBERTa		BioMed-RoBERTa		BioMed-RoBERTa-Long	
A	1. the	6. ib	1. ib	6. event	1. trial	6. to
	2. survival	7. V	2. trial	7. treatment	2. of	7. patients
	3. (8. 1	3. patients	8. azine	3. the	8. events
	4. is	9. randomly	4. phase	9. CL	4. The	9. CL
	5.)	10. patients	5. mg	10. group	5. TA	10. CNS
B	1. survival	6. HL	1. survival	6. in	1. patients	6. Ther
	2. (7. cohort	2. L	7. lect	2. K	7. endpoint
	3. patients	8. %	3. %	8. P	3. the	8. D
	4. outcome	9. tumor	4. a	9. free	4. survival	9. oma
	5. median	10. response	5. associated	10. endpoint	5. ase	10. OR
C	1. ,	6. with	1. HL	6. mutation	1. HL	6. au
	2. the	7. a	2. cases	7. oma	2. Disease	7. Von
	3.)	8. or	3. patients	8. BRA	3. Hipp	8. mutations
	4. and	9. an	4. with	9. and	4. Lind	9. mutation
	5. –	10. gene	5. V	10. usions	5. V	10. unknown
D	1. is	6. that	1. cells	6. inhibitor	1. mice	6. cular
	2. ib	7. never	2. mutations	7. signaling	2. in	7. the
	3. cells	8. free	3. mice	8. that	3. cell	8. and
	4. mice	9. pl	4. mutant	9. ogenic	4. models	9. Ther
	5. As	10. V	5. CNS	10. inhibition	5. a	10. mutations
E	1. the	6. 1	1. V	6. untreated	1. V	6. of
	2.)	7. (2. CNS	7. children	2. the	7. that
	3. V	8. free	3. d	8. transcript	3. in	8. mutants
	4. ib	9. CC	4. smoker	9. hazard	4. TOR	9. imus
	5. is	10. ;	5. event	10. ations	5. ase	10. survival